Background: Currently, no drug is available to directly target the signaling molecules involved in the pathogenesis of diabetic nephropathy (DN); only antihypertensive and antidiabetic drugs are in clinical use. In the present study, the therapeutic effects of a active fraction of tubers from Pueraria tuberosa (hereafter referred to as PTY-2) were investigated in streptozotocin (STZ)-diabetic rats with DN, with particular emphasis on its effects on extracellular matrix (ECM) accumulation and matrix metalloproteinase (Mmp)-9 expression in kidney tissue. Methods: Rats were injected with 55 mg/kg, i.p., STZ. After 40 days, rats were divided into groups as follows (n = 6 per group): Group 1, age-matched rats not injected with STZ (non-diabetic control); Group 2, STZ-diabetic DN rats; and Group 3, PTY-2 (30 mg/100 g, p.o.)-treated DN rats. After 20 days treatment, the effects of PTY-2 on serum urea and creatinine concentrations, urinary levels of glucose, creatinine, protein, and ketone bodies, and urine pH were determined. Kidney tissue was evaluated for Mmp-9 expression and histological changes. Results: Blood glucose, serum urea, creatinine, and urine protein levels were significantly higher, and creatinine clearance was significantly lower, in Group 2 versus Group 1 rats. There was a higher degree of glomerulosclerosis, expansion of the mesangial matrix, and excess ECM deposition and eosinophilic casts in kidneys from Group 2 versus Group 1 rats. Furthermore, Mmp-9 activity and expression were significantly reduced in kidney homogenate of Group 2 versus Group 1 rats. Interestingly, PTY-2 treatment significantly reversed all these changes in DN rats. Conclusion: Treatment of DN rats with PTY-2 significantly attenuated the severity of DN by increasing the expression and activity of Mmp-9, consequently degrading the ECM accumulated in kidney tissue.
Introduction
Chronic kidney disease (CKD), both primary and secondary, is one of the leading causes of mortality. Its link to hypertension and diabetes is well documented, and early intervention is required to avoid progression to CKD. Approximately 41 %-60 % of diabetic patients may end up with diabetic nephropathy (DN). 1 Some of these patients develop end-stage renal disease (ESRD). Management of later stages of CKD is expensive, placing a considerable financial burden on society. The pathogenesis of CKD is known to include deregulation of the polyol pathway, the formation and accumulation of advanced glycation end-products (AGEs), 2 the hexosamine pathway, which is responsible for the excess glycation of proteins, 3 the activation of protein kinase C (PKC), 4 growth factors, cytokines, 5 poly(ADP-ribose) polymerase (PARP), and mitogen-activated protein kinase (MAPK), 6 and the accumulation of free radicals. 7 However, currently there is no drug available that can treat DN, with only hypoglycemic and antihypertensive drugs in clinical use. Although some drugs have been developed specifically for the treatment of DN, they have not proven effective in clinical trials. 8 Thus, novel therapeutic agents are needed that can target different signaling molecules involved in pathogenesis of DN and exhibit fewer side effects. The use of herbal medicines would be beneficial because of their existing clinical use and reported multitarget actions. Herbal medicines are natural cocktails of secondary metabolites and there is considerable experimental data indicating their benefits over single isolated phytochemicals. [9] [10] [11] In experimental animal models, DN is defined as increased urinary albumin excretion, with low creatinine clearance, a decreased glomerular filtration rate, and high serum urea and creatinine levels. Structural changes in animal models of DN include glomerulosclerosis, thickening of the basement membrane, and excessive accumulation of eosinophilic casts (EC) and extracellular matrix (ECM). [12] [13] [14] These changes are attributed to increased synthesis or decreased degradation of the ECM. 15 Persistent hyperglycemia produces extra advanced glycation end-products (AGEs) and activates protein kinase C (PKC), further increasing the expression of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β and connective tissue growth factor (CTGF). These changes result in glomerular hypertrophy, increased permeability to macromolecules, albuminuria, basement membrane thickening, and cast deposition. 16 Matrix metalloproteinases (MMPs) play an important role in the degradation of the ECM. 17 The MMPs belong to the group of zinc-dependent enzymes and are broadly divided into collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs, among others. 18 Of the MMPs, the gelatinases MMP-2 and MMP-9 are primarily involved in the pathogenesis of DN, with significant reductions in both their expression and activity in DN. 15, 19 However, some reports indicate biphasic modulation of MMP-9, with initial activation followed by a decline in later stages of DN. 20 In another study, similar biphasic response is reported for activity of superoxide dismutase and catalase in pathogenesis of acute kidney injury induced by cisplatin and also hyperlipidimia induced by high fructose diet. 21 The role of MMP-9 in the secretion of growth factors and cytokines has also been reported. 22, 23 Because of the limited availability of allopathic drugs, the use of herbal medicines either as drugs or food supplements is being explored. In their crude form, herbal medicines are a natural cocktail of phytochemicals and may act different signaling pathways to achieve a protective response. 24, 25 Some plants described in the Ayurveda, the Indian system of medicine, including Crataeva nurvala and Tribulus terrestris, have been reported as to be nephroprotective, 26 but there are no reports regarding the nephroprotective effects of Pueraria tuberosa (Roxb. ex. Willd.) DC (Leguminosae or Fabaceae), known as Indian Kudzu or Vidarikand.
In the present study we explored the effects of a patented, partially purified polar fraction of the tuber of P. tuberosa, hereafter referred to as PTY-2. The P. tuberosa tubers are already used clinically in Ayurveda to treat various ailments and as promoters of general health. 27 The tubers are rich in flavones, isoflavanoids, and phytoestrogens, with the major constituents being puerarin, daidzein, genistein, puetuberosanol, and tubersin. 28 Previous studies have reported on the antioxidant, 29 anti-inflammatory, 30 and nephroprotective 31 (against acute kidney damage) effects of the P. tuberosa tubers. Others studies have also reported on the antihyperglycemic, antihyperlipidemic, and antifertility properties of P. tuberosa tubers. 32, 33 In the present study, we investigated the hypothesis that PTY-2 would prevent the progression of DN by degrading the accumulated ECM by activating Mmp-9, resulting in repair to the glomerular damage. To test this hypothesis, we assessed the effects of PTY-2 on Mmp-9 gene expression and activity and correlated these effects with kidney function and histological changes in he kidney tissue of streptozotocin (STZ)-induced DN rats.
Methods

Preparation of PTY-2 extract
Tubers of P. tuberosa were purchased from a local market and their authenticity was ascertained as described earlier. 29 The coarse powder of P. tuberosa tubers was extracted with a mixture of water and alcohol in a continuous Soxhlet extractor and a solvent-free extract was prepared by distillation; (patent application no: 2751/ DEL/2008) the extract was characterized by thin layer chromatography (TLC) to avoid batch-to-batch variation, as reported previously. 34 
Experimental protocol and induction of DN
The experimental protocol was approved by the Animal Welfare Ethics Committee of the Institute of Medical Sciences (IMS), Banaras Hindu University (BHU; Letter no. Dean/2011-12/208). Inbred albino rats of the Charles Foster strain (male; 100-120 g) were purchased from the Central Animal House of IMS BHU and acclimatized to laboratory conditions for 7 days, with free access to normal standard chow diet and tap water. After a week, overnight-fasted rats were injected with STZ (55 mg/kg, i.p.), freshly prepared in citrate buffer, pH 4.5. Control non-diabetic rats (Group 1; n = 6) were injected with the same volume of citrate buffer. Four days after the STZ injection, blood sugar was assessed in overnight-fasted rats using a glucometer (SD Biosensor India, New Delhi, India) and 80 % of rats were found to have developed diabetes; rats with blood glucose levels >17 mmol/L were considered diabetic. 35 These rats were maintained in the diabetic condition for 40 days, with a 90 % survival rate, to achieve DN. Each rat was placed in a metabolic cage to collect urine for biochemical analysis and rats with proteinuria were randomly divided into a DN control group (Group 2) and a PTY-2-treated group (Group 3; n = 6 rats in each group). Group 1 rats were maintained in parallel as an age-matched control group.
Treatment protocol
Rats in Groups 1 and 2 were administered drug vehicle (20 % Tween 20), p.o., for a further 20 days, whereas rats in Group 3 were treated with PTY-2 (30 mg/100 g, p.o.) for a further 20 days. After the 20 days treatment (i.e. after a total of 60 experimental days), blood and urine samples were collected from each rat for biochemical analysis and the rats were then killed. Both kidneys were removed from the rats in all groups for histological analysis, zymography and reverse transcription-polymerase chain reaction (RT-PCR). The experiments were performed using different doses of PTY-2 (10-30 mg/100 g), revealing that PTY-2 had a dose-dependent nephroprotective effect (data not shown), but the results for only one dose are reported herein because although the lower doses had a protective effect, the values were not highly significant.
Biochemical and metabolic parameters
Blood glucose was measured by glucometer at 40 and 60 days. Serum urea and creatinine (Cr) were also determined at 40 and 60 days using commercially available kits (Accurex Biomedical, Mumbai, India). Urinary Cr clearance (CCr; mL/kg per min) was calculated using the formula (urine Cr/serum Cr × urine volume). Body weight was determined weekly. A kidney index was calculated using the formula (kidney weight/body weight × 1000).
Histological studies
Excised kidneys were fixed in Bouin's fixative and subsequently processed for rehydration and dehydration and poured into melted wax for block preparation as described previously. 36 Thin microsections (5 μm) of kidney blocks were cut using a rotary microtome (Medimeas Instruments, Ambala Cantonment, India) and stained with hematoxylin-eosin (H&E) and periodic acid-Schiff (PAS) reagent before being examined under a microscope (Eclipse 50i; Nikon, Kanagawa, Japan) loaded with imaging software (NIS Elements Basic Research; Nikon).
Determination of glomerulosclerotic and EC indices
The degree of glomerular damage was quantified using the glomerulosclerotic index (GSI). To that end, PASstained sections were examined at a magnification of ×400, with 100 glomeruli per section randomly selected for scoring using a semiquantitative method, whereby the degree of glomerular damage was scored as follows: 0, normal glomeruli; 1, ≤25 % sclerosis; 2, ≤50 % sclerosis; 3, ≤75 % sclerosis; and 4, >75 % sclerosis. The GSI was calculated using the following equation:
where Nx is the number of glomeruli with a particular score [1] [2] [3] [4] for a given section. 37 To determine the EC index (ECI), H&E-stained sections were examined at a magnification of ×400, with 1000 tubules randomly counted per section in 50 fields. The number of tubules with ECs was counted and divided by the total number of tubules counted. 38 
Zymography for gelatinase activity
After dissection, kidneys were washed with ice-cold phosphate-buffered saline (PBS), and a 10 % homogenate (w/v) was prepared using ice-cold lysis buffer (50 mmol/L Tris, pH 7.6, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 % Triton X-100, 0.1 % sodium dodecyl sulfate [SDS], 1 mmol/L sodium orthovanadate, protease inhibitor cocktail and 1 mmol/L phenylmethylsulfonyl fluoride). The tissue lysate was centrifuged at 20 289 g (R-248 rotar) (Remi laboratory instrument Remi House, Cama Industrial Estate Walbhat Road, Goregaon (East) Mumbai, IN-DIA) for 15 min at 4°C and the clear supernatant was saved for zymography to assess gelatinase activity, as described previously. 39 Briefly, the kidney homogenate (20 μg protein) was mixed with sample buffer (1 mol/L Tris-HCl, pH 6.8, glycerol, 10 % (w/v) SDS, 0.1 % bromophenol blue) and separated on a 10 % SDS polyacrylamide gel containing 1 % gelatin at 110 V in a cold-room under non-reducing conditions. After electrophoresis, gels were washed with 2.5 % Triton X-100 to displace the SDS and further equilibrated with developing buffer (50 mmol/L Tris, 200 mmol/L NaCl, 5 mmol/L CaCl 2 , 0.02 % Brij-35, pH 7.8) for 30 min, followed by overnight incubation with fresh developing buffer at 37°C. The next day, the gels were stained with 0.1 % Coomassie Brilliant Blue R-250 (Sigma, St Louis, MO, USA; dissolved in 40 % methanol, 10 % acetic acid) for 2 h at room temperature, destained (with 40 % methanol, 10 % acetic acid), and bands analyzed using alpha-imager software. (AlphaImager ™ IS-2200, protein simple-a biotech brand, Orchard Parkway San Jose, California, USA).
Reverse transcription-polymerase chain reaction for Mmp9
Total RNA was extracted from kidney tissue using TRIzol reagent. Then, 5 μg total RNA was reverse transcribed with Superscript II RNase H-reverse transcriptase (Fermentas, Thermo Fisher Scientific, Waltham, MA, USA) using random hexamers according to the manufacturer's instructions. The primers used in the present study were as follows: Mmp9, 5′-TGTACCGTATGGTTACAC-3′ (forward) and 5′-CCGCGACACCAAACTGGAT-3′ (reverse); and glyceraldehyde-3-phosphate dehydrogenase (Gapdh), 5′-AGTGAGGAGCAGGTTGAGGA-3′ (forward) and 5′-GAGGAGGGGAGATGATGTGA-3′. Amplification was performed using
For Gapdh, the PCR sequence consisted of initial denaturation at 94°C for 3 min, followed by 35 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for 45 s, and a final extension at 75°C for 5 min. The amplified products were separated by electrophoresis on a 2 % agarose gel. The optical density of Mmp9 was determined using imagequant LAS500 (GE Healthcare Life Sciences, XXX, Sweden), and was normalized against that of Gapdh.
Statistical analysis
Results are expressed as the mean ± SD and all statistical comparisons were made using one-way analysis of variance (ANOVA) followed by post hoc analysis with Dunnett's test. Statistical significance was set at twotailed P ≤ 0.05.
Results
Effects of PTY-2 on biochemical parameters
There was a significant increase in serum urea and Cr concentrations at 60 days in Group 2 rats (DN control) compared with rats in Group 1 (non-diabetic control). Treatment with PTY-2 (30 mg/100 g; Group 3) significantly reversed the changes seen in Group 2 rats. Specifically, after 20 days treatment (= Day 60), serum urea and Cr concentrations were reduced by approximately 51.6 % and 50 %, respectively, compared with values in Group 2 rats. In addition, there was a 147 % increase in urinary Cr and a 315 % increase in CCr in Group 3 versus Group 2 rats. The increased serum Cr concentrations in Group 2 rats are linked to low CCr because of kidney damage ( Table 1) . Treatment of diabetic rats with PTY-2 increased CCr to within the normal range (Table 1) . Interestingly, Group 2 (DN control) rats exhibited significant loss of body weight at 60 days (Table 1) , which was time dependent (data not shown), and this loss in body weight was halted at 40 days when PTY-2 treatment was initiated, meaning that there the body weight of rats in Group 3 at 60 days was significant greater than that of rats in Group 2 ( Table 1) .
Effects of PTY-2 on urinary parameters
The urine of DN control rats (Group 2) had an alkaline pH, a high degree of proteinuria, glycosuria and high levels of ketone bodies. Interestingly, PTY-2 treatment (Group 3) significantly reversed the increased proteinuria, glycosuria and ketone bodies, although values remained higher than in the normal control group (Table 2) .
Histological examinations
Thin sections of kidneys from non-diabetic rats (Group 1) showed a normal glomerulus surrounded by Bowman's capsule without any changes in structure (Figs 1a,2a) . However, thin sections of kidney from DN control rats (Group 2) showed cloudy swelling with deposition of ECs in the proximal convoluted tubule, along with the dilation of the tubules (Fig. 1b) . In addition, thickening of the glomerular basement membrane and excessive deposition of ECM was seen in sections from Group 2, leading to obliteration of the capillary lumen, a sign of glomerulosclerosis (Fig. 2b) . Sections from Group 3 revealed significant improvement in all these parameters following PTY-2 treatment: normal glomeruli with less tubular necrosis were seen, along with decreased basement membrane thickening and less ECM deposition (Fig. 2c) .
Effects of PTY-2 on the GSI and ECI
Quantitative analysis revealed that the GSI was markedly increased in Group 2 compared with Group 1 rats (2.06 ± 0.12 vs 0.21 ± 0.06, respectively; P < 0.001). Interestingly, PTY-2 treatment reduced glomerulosclerosis in DN rats by approximately 50 % of that seen in the Table 1 Effects of the active fraction of tubers from Pueraria tuberosa (PTY-2) on body weight, blood sugar and kidney function in streptozotocin-induced diabetic rats with diabetic nephropathy Data are the mean ± SD (n = 6 in each group). * P < 0.05, ** P < 0.01 compared with Group 1, the non-diabetic control group; † P < 0.05 compared with Group 2, the untreated diabetic nephropathy group. Group 3, PTY-2-treated diabetic rats; Cr, creatinine; CCr, creatinine clearance. Data are the mean ± SD (n = 6 in each group).
** untreated DN rats (1.02 ± 0.07; P < 0.001; Fig. 3 ). Similarly, the ESI was significantly increased in kidney thin sections of Group 2 versus Group 1 rats (1.24 ± 0.14 vs 0.02 ± 0.01; P < 0.001). In Group 3 rats, PTY-2 treatment significantly reversed the increase in the ECI seen in untreated DN rats by approximately 59 % (0.50 ± 0.03; P < 0.001).
Gelatinase activity of Mmp-9
Gelatin zymography was used assess collagenase activity, whereby a protein band of specific collagen is degraded on the gel, resulting in a reduction in the staining of the collagen band. The degree of the reduction in staining is proportional to the activity of the particular collagenase. In the present study we evaluated the activity of Mmp-9 (92 kDa). As indicated in Fig. 4 , Mmp-9 activity was significantly decreased in the kidney homogenate of DN control rats (Group 2), but was increased (P < 0.05) by approximately 1.6-fold after PTY-2 treatment of DN rats (Group 3).
Effects of PTY-2 on Mmp9 mRNA expression
To provide further support to the findings regarding Mmp-9 activity, Mmp9 mRNA expression was evaluated using RT-PCR. Similar to the results for Mmp-9 protein, Mmp9 mRNA expression was significantly reduced in kidney tissues of Group 2 versus Group 1 rats (P < 0.05), and PTY-2 treatment of DN rats (Group 3) significantly (P < 0.05) increased Mmp9 mRNA expression by approximately 1.8-fold compared with that seen in untreated DN rats (Fig. 5 ).
Discussion
Earlier, we reported on the nephroprotective effects of P. tuberosa in an experimental model of acute kidney damage, 31 but to date no studies have evaluated the effects of any products of P. tuberosa in DN. In the present study, we evaluated the effects of an extract of the tubers of P. tuberosa, a medicine used in the Ayurvedic system as an anti-aging drug. 28 The findings of the present study provide evidence that PTY-2 improves the kidney function in STZ-diabetic (DN) rats. Specifically, PTY-2 treatment of DN rats ameliorated glomerulosclerosis, expansion of the mesangial matrix, ECs, and proteinuria, with evidence of a hypoglycemic response in DN rats. However, these histological and biochemical changes in kidney function may not be due solely to a hypoglycemic response, because blood glucose in PTY-2 treated rats was decreased by only 14 %, whereas improvements in serum urea and Cr were 51.6 % and 50 %, respectively. Thus, it could be suggested that the nephroprotective effect of PTY-2 is due not only to its hypoglycemic effects, 40 but also to direct effects on other pathogenic targets in the signaling cascade. In addition, the improvement in renal function and subsequent improvements in the quality of the urine support a nephroprotective potential for PTY-2. Similar results following treatment of DN rats with angiotensinconverting enzyme inhibitors 19 are consisting with the findings of the present study.
Accumulation of the ECM is one of the characteristics of glomerosclerosis 41 and this was evident in Group 2 (DN control) rats, which also had an increased GSI. These rats also exhibited decreased Mmp-9 activity and Mmp9 mRNA expression in renal tissues. This inverse correlation between ECM accumulation and Mmp-9 gene expression and activity is consistent with earlier reports. 15, 19 Treatment of DN rats with PTY-2 (Group 3) significantly ameliorated ECM deposition and upregulated both Mmp-9 activity and Mmp9 mRNA expression.
The MMPs, along with tissue-specific inhibitors of metalloproteinases (TIMPs), are involved in the regulation of mesangial ECM turnover, 42 which was not evaluated in the present study. Thus, the possibility that the effects of PTY-2 on Mmp-9 activity involve effects on TIMP cannot be ruled out and require further investigation.
In addition, PTY-2 treatment reduced proteinuria, which is linked to podocyte damage. 43 This cellular protection could be attributed to inhibition of apoptosis in podocytes, although we did not examine this possibility. Because P. tuberosa has antioxidant 29 and antiinflammatory 30 effects, it could potentially have a role in podocyte protection. The presence of a variety of isoflavones and polyphenols in polar fractions of P. tuberosa extracts could explain these actions. 44 Because the pathogenesis of DN is multi-etiological, crude extracts of plants may be more useful because they are a natural cocktail of various phytomolecules, all of which could act synergistically to achieve their therapeutic goal. [9] [10] [11] The present study paves a path for further studies with this plant material to develop a drug for the treatment of DN, which usually leads to ESRD, a major cause of premature death in diabetic patients. Meanwhile, the findings of the present study support the existing clinical use of P. tuberosa in Ayurveda and suggest the need for observational studies of P. tuberosa as a food supplement to manage DN.
Conclusions
We have shown in the present study that PTY-2, a semipurified polar fraction of the tubers of P. tuberosa, improves the condition of DN. Specifically, PTY-2 treatment of DN rats decreased the diabetic-induced increases in serum urea, Cr, and proteinuria, and increased the diabetic-induced reduction in CCr. In addition, PTY-2 treatment attenuated ECM accumulation, glomerulosclerosis, and ECM thickening by activating Mmp-9. 
